Post-Effective Amendment No. 1 to Form S-3

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QdZN/cYKFirzm48agdIfLmiiwwEeJkd9WaYl/Q3RL9OwtxO0ThvQeAAWDBNvjhws Tqwtuw/McLVVpAHUe7bm6w== 0001193125-09-053395.txt : 20090313 0001193125-09-053395.hdr.sgml : 20090313 20090313121323 ACCESSION NUMBER: 0001193125-09-053395 CONFORMED SUBMISSION TYPE: POS AM PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090313 DATE AS OF CHANGE: 20090313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PANACOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001040017 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 113238476 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POS AM SEC ACT: 1933 Act SEC FILE NUMBER: 333-123781 FILM NUMBER: 09678604 BUSINESS ADDRESS: STREET 1: 134 COOLIDGE AVE CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-1551 MAIL ADDRESS: STREET 1: 134 COOLIDGE AVE CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: V I TECHNOLOGIES INC DATE OF NAME CHANGE: 19980209 POS AM 1 dposam.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3

As filed with the Securities and Exchange Commission on March 13, 2009

Registration No. 333-123781

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO

FORM S-3

REGISTRATION STATEMENT

UNDER THE SECURITIES

ACT OF 1933

Panacos Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware		11-3238476
(State or other jurisdiction		(IRS Employer
of incorporation or organization)		Identification Number)

134 Coolidge Avenue Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

Alan W. Dunton, M.D. President and Chief Executive Officer Panacos Pharmaceuticals, Inc. 134 Coolidge Avenue Watertown, Massachusetts 02472 (617) 926-1551		Copies to: Megan N. Gates, Esq. Mintz, Levin, Ferris, Glovsky & Popeo, P.C. One Financial Center Boston, MA 02111 (617) 542-6000
(Name, address, including zip code, and telephone number, including area code, of agent for service)

Not Applicable

(Approximate date of commencement of proposed sale to the public)

DEREGISTRATION OF UNSOLD SECURITIES

On April 4, 2005, Panacos Pharmaceuticals, Inc., formerly known as V.I. Technologies, Inc. (the “Company”), filed a Registration Statement on Form S-3, as amended (File No. 333-123781) (the “Registration Statement”), to register up to 14,717,497 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). This offering has been terminated because the Company intends to deregister its Common Stock under the Securities Exchange Act of 1934, as amended. Consequently, in accordance with an undertaking made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offering, the Company hereby removes from registration the securities of the Company that are registered but unsold under the Registration Statement.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to its Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts on March 13, 2009.

PANACOS PHARMACEUTICALS, INC.

/s/ Alan W. Dunton, M.D.

Alan W. Dunton, M.D.

President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.


Signature	Title	Date

/s/ Alan W. Dunton, M.D.	President and Chief Executive Officer and Director	March 13, 2009
Alan W. Dunton, M.D.	President and Chief Executive Officer and Director

/s/ Robert B. Pelletier, CPA, MBA	Vice President of Finance and Principal Accounting Officer	March 13, 2009
Robert B. Pelletier, CPA, MBA	Vice President of Finance and Principal Accounting Officer

/s/ Laurent Fischer, M.D.	Director	March 13, 2009
Laurent Fischer, M.D.

/s/ Jeremy Hayward-Surry	Director	March 13, 2009
Jeremy Hayward-Surry

-----END PRIVACY-ENHANCED MESSAGE-----